Slide 1: Investor Presentation
Exhibit 99.1 Investor Presentation June 2014 NASDAQ: KMDA
Slide 2: Forward Looking Statement
Forward Looking Statement This presentation is not intended to provide investment or medical advice. It should be noted that some products under development described herein have not been found safe or effective by any regulatory agency and are not approved for any use outside of clinical trials. Th
Slide 3: Kamada Overview
Kamada Overview Key Statistics • Founded in 1990 and based in Weizmann Science Park, Israel • Employees: ~300 (1) 1 • Listed on NASDAQ since 2013 & TASE since 2005 (KMDA) • Current market capitalization: ~$300MM (2) • Cash, cash equivalents and ST investments: $71MM(1) • AAT deficiency (AATD) is a g
Slide 4: Diversified Product Portfolio with Extended Global Reach
Diversified Product Portfolio with Extended Global Reach Diverse Portfolio of Predominantly Plasma-Derived Protein Therapeutics Global Presence with Exposure to Emerging Markets Respiratory Glassia® Alpha-1 Antitrypsin (human) KamRAB™ Anti-rabies immunoglobulin (human) Proprietary KamRho (D) IM Rho(
Slide 5: Glassia Is A Differentiated Product
2 Glassia® Is A Differentiated Product Key Product Advantages AATD (IV) Product Sales and Milestone Revenues P Glassia® is the first and only liquid, ready-to-use, IV Sold in 7 countries, with majority of sales in the US plasma-derived AAT product P No reconstitution required, reducing risk of conta
Slide 6: Kamada Investment Highlights
Kamada Investment Highlights Rapidly Growing, Globally Positioned Biopharmaceutical Company - Focused on Orphan Diseases and Plasma Derived Protein Therapeutics Flagship Product Glassia® Approved for Alpha-1 Antitrypsin Deficiency - Has a Unique and Differentiated Product Profile and Represents an E
Slide 7: Positive Industry Dynamics Favorable Growth Forecasts
1 Positive Industry Dynamics Favorable Growth Forecasts The Global Market for Plasma-Derived Protein Therapeutics § Plasma-derived protein therapeutics are drugs that are $ Bn fractionated and purified from human plasma and its derivatives CAGR = 9.1% – Treat a variety of diseases including chronic,
Slide 8: Sustainable Market with Strong Growth Potential
2 Sustainable Market with Strong Growth Potential North America and Europe AATD Patient Counts (000s) § Patients suffering from AAT Deficiency (“AATD”) remain under-identified and under-treated – Only ~5% of cases treated in the US and ~2% in EU ~ § Simple blood test for diagnosis expected to impact
Slide 9: Strategic Partnership with Baxter
3 Strategic Partnership with Baxter P Sales to Baxter commenced in September 2010 P Agreements: distribution, technology license and fraction IV supply P Product: AAT IV (Glassia®), including future AAT IV P Territories: US, Canada, Australia and New Zealand P Milestone and upfront revenues: $45MM (
Slide 10: Pipeline
4 Product Indication Phase I Phase II Phase III Market Partners 1 Intravenous AAT AAT Deficiency FDA Approved (2010) US: 2 D1-AAT (IV) Type 1 Completed Ph II/III In Process US: Diabetes* 3 G1-AAT (IV) GVHD Ph I/II In Process US: EU: Study Completed 4 Inhaled AAT EU: AAT Deficiency* US: Ph II In Proc
Slide 11: Inhaled AAT Highlights; Strategic Partnership with Chiesi
4 Inhaled AAT Highlights Strategic Partnership with Chiesi P First and only Inhaled AAT product for AATD ü Chiesi distribution agreement as of August 2012 – Device and drug combination enable optimal size ü Agreement: Chiesi responsible for S&M, patient ID, particles delivered directly to diseased t
Slide 12: Inhaled AAT for AATD is a Novel, Late-Stage Pipeline Product
4 Inhaled AAT for AATD is a Novel, Late-Stage Pipeline Product AAT is inhaled by subjects who are AAT Deficient and experience lung inflammation and occurrence of Sound scientific rationale emphysema Targets site of action Product is directed to the site of action - the diseased lung tissue Depositi
Slide 13: eFlow Device Technology Highlights; Strategic Partnership with PARI
4 eFlow Ò Device Technology Highlights eFlow Ò Device ü CE marked in EU ü Generates particle size of ~3 microns, well- suited for an appropriate lung deposition of AATD, CF and COPD ü Enables direct access to the diseased lung Strategic Partnership with PARI tissues P PARI agreements for joint devel
Slide 14: Phase II/III EU and Phase II US Trial Designs
4 Phase II / III EU Phase II US Description § Randomized; Sample size of ~ 36-40 subjects § Double blind, placebo controlled, randomized Route & § Inhalation of human AAT; two dosage groups (80mg § Inhalation of human AAT, 160mg total, twice daily Dosage Form and 160mg daily); eFlow® device ~10-15 m
Slide 15: Inhaled AAT for AATD: Preliminary Results Phase II/III
Inhaled AAT for AATD: Preliminary Results Phase 4 II/III § Primary endpoint: time to first moderate/severe exacerbations - preliminary results didn’t show difference between placebo and AAT group § Secondary : frequency (rate) of exacerbations and severity of first exacerbations, lung function § Ini
Slide 16: Indicative Development Timeline
4 Indicative Development Timeline: Meeting with Completion of US launch for FDA re Inhaled Phase II Inhaled Inhaled AAT for AAT for AATD AAT for AATD AATD in clinical trial (if approved) the US 2014 2015 2016 Phase II/III Inhaled EU launch for Inhaled AAT for AAT for AATD Inhaled AAT for AATD MAA co
Slide 17: D1, B1 and C1 AAT Studies
4 D1: Type-1 Diabetes B1: Bronchiectasis C1: Cystic Fibrosis § Completed Phase I/II § Completed Phase II § Completed Phase II – Open Label, Proof of Concept, Study § Double-blind, placebo controlled § Double-blind, placebo controlled of the Safety, Tolerability and trials completed study Stage (1) E
Slide 18: Cystic Fibrosis Treatment Rationale
4 CF disease is characterized by: NE Accumulation CF treatment rationale is based on: 1. The administration of the AAT is to address the imbalance of elastase and antiprotease. 2. Administration of AAT will help to prevent destruction of the lung architecture , prevent / reduce bacteria colonization
Slide 19: Studies Have Shown That AAT Protects Beta Cell Islets
5 Studies Have Shown That AAT Protects Beta Cell Islets • Delays the onset of autoimmune diabetes Type 1 Diabetes Statistics • more than 10 million suffer from T1D globally • Reduces the incidence of diabetes • 100,000 new patients diagnosed annually • Inhibits insulitis and beta-cell apoptosis • In
Slide 20: Preservation of beta cells correlates with reduced risk of long term complications
5 Preservation of beta cells correlates positively with reduced risk of long term complications • The Diabetes Control and Complications Trial “We acknowledge the evidence (DCCT*) from the DCCT and other studies and the U.K. Prospective Diabetes Study that have demonstrated clinical demonstrated tha
Slide 21: Clinical Development for Newly Diagnosed Type-1 Diabetes
5 Clinical Development for Newly Diagnosed Type‐1 Diabetes: New Exciting Prospects End-of-study slope analysis of C-peptide[max] and C- HbA1C data indicated that almost all patients reached peptide[AUC] revealed no significant changes from baseline glycemic control •AUC% for C-peptide decreased 23%
Slide 22: Proprietary Technology Platform and Fully-Invested Manufacturing Facility
6 Proprietary, Innovative and Fully-Invested Manufacturing Benefits Patented Technology Platform Facility § Patent protected: § FDA approved since 2010 § Enables manufacturing of plasma- Chromatography-based derived protein therapeutics with purification process differentiated product profiles § cGM
Slide 23: Financials
Financials @ kamapa =
Slide 24: Investment Driven By Multiple Pillars of Growth
6 Compelling Investment Driven By Multiple Pillars of Growth Additional The Kamada Unencumbered New Geographies Pipeline Products Pillars § C1-AAT (IH): Inhaled AAT for § Potential to sell Cystic fibrosis Existing Anchor AATD in existing and new completed Phase II Products Europe & US products into
Slide 25: Strong Financial Profile with Revenue Growth and Expanding Profitability
7 Strong Financial Profile with Revenue Growth and Expanding Profitability § Pipeline products expected to accelerate revenue growth § Better product mix expected to improve gross margin § Strategic partnership model results in efficient operating expenses § Stable, profit generating revenue stream
Slide 26: Sustained and Rapid Growth Made Kamada EBITDA Positive Within 3 Years
7 Sustained and Rapid Growth has Made Kamada EBITDA Positive Within 3 Years of Growth $MM FY2009 FY2010 FY2011 FY2012 FY2013 Proprietary 10 23 35 47 51 Products Growth 130% 54% 32% 9% Distribution 4 11 24 26 20 Growth 187% 110% 8% (23%) Total Revenues 14 34 59 73 71 Growth 146% 73% 22% (3%) Gross Pr
Slide 27: Consistent Track Record of Execution
Consistent Track Record of Execution Initial Public Offering on the Tel Aviv Stock Exchange (KMDA) August Strategic agreement with PARI 2005 US FDA approval for Glassia® Strategic agreement with Baxter & First Glassia® sale in the US Strategic agreement for Rabies in the US with Kedrion Anti-Snake V
Slide 28: Future Milestones and Value Creation
Future Milestones and Value Creation Milestone Date Phase II/III Inhaled AAT for AATD trial (EU) final results 3Q14 MAA submission for Inhaled AAT for AATD 2014 Initiation of Phase ll for inhaled AAT for CF trial in the US 2014 Completion of Phase III for the Rabies lg in the US 2014 Completion of P
Slide 29: Kamada Investment Highlights
Kamada Investment Highlights Rapidly Growing, Globally Positioned Biopharmaceutical Company - Focused on Orphan Diseases and Plasma Derived Protein Therapeutics Flagship Product Glassia® Approved for Alpha-1 Antitrypsin Deficiency Disorder - Has a Unique and Differentiated Product Profile and Repres
Slide 30: Thank you.
Thank you. www.kamada.com @ kamapa =